$2.67
+0.09 (+3.49%)
Open$2.54
Previous Close$2.58
Day High$2.72
Day Low$2.51
52W High$21.15
52W Low$12.82
Volume—
Avg Volume771.0K
Market Cap4.62M
P/E Ratio48.00
EPS$0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+524.3% upside
Current
$2.67
$2.67
Target
$16.67
$16.67
$13.69
$16.67 avg
$25.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 586.6K | 551.3K | 523.6K |
| Net Income | -23,280 | -22,798 | -22,545 |
| Profit Margin | -4.0% | -4.1% | -4.3% |
| EBITDA | -32,929 | -31,435 | -27,673 |
| Free Cash Flow | -20,426 | -16,844 | -21,611 |
| Rev Growth | +23.9% | +11.9% | +23.1% |
| Debt/Equity | 0.35 | 0.37 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |